Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness.

导出 LinkOut

翻译打印收藏纠错

作者： Raquel,Rivera-Díaz ^[1] ; Mar,LLamas-Velasco ^[2] ; Mercedes,Hospital ^[3] ; Isabel,Martín ^[4] ; Ofelia,Baniandrés ^[5] ; Diana,Ruíz-Genao ^[6] ; Pablo,de la Cueva ^[7] ; Carmen,García-Donoso ^[1]

作者单位： Dermatology Service, Universitary Hospital 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain. ^[1] Dermatology Service, Universitary Hospital La Princesa, Madrid, Spain. ^[2] Dermatology Service, Universitary Hospital Puerta de Hierro Majadahonda, Madrid, Spain. ^[3] Dermatology Service, Universitary Hospital de Getafe, Madrid, Spain. ^[4] Dermatology Service, Universitary Hospital Gregorio Marañón, Madrid, Spain. ^[5] Dermatology Service, Universitary Hospital Fundación Alcorcón, Madrid, Spain. ^[6] Dermatology Service, Universitary Hospital Infanta Leonor, Madrid, Spain. ^[7]

关键词 Psoriasis biologics effectiveness interleukin-23 real-world data risankizumab therapy-systemic

主题词抗体, 单克隆(Antibodies, Monoclonal);生物制品(Biological Products);人类(Humans);银屑病(Psoriasis)

DOI 10.1080/14712598.2022.2012567

PMID 34879214

发布时间 2022-04-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交